Phaserx Inc Cmn (PZRX) 2.50 $PZRX PhaseRx to Present at

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Phaserx Inc Cmn (PZRX) 2.50 $PZRX

PhaseRx to Present at the 2016 Aegis Growth Conference
PR Newswire - Wed Sep 14, 7:30AM CDT
PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA products to correct life-threatening inherited liver diseases in children, today announced that the company will be presenting at the 2016 Aegis Growth Conference. Robert W. Overell, Ph.D., president and chief executive officer, will provide an overview of the company and its development stage programs on Wednesday, September 21, 2016 at 3:30 p.m. PDT (6:30 p.m. EDT). The investor conference will be held from September 21-22, 2016 at the Encore at Wynn in Las Vegas.
PZRX: 2.50 (-0.09)

PhaseRx Appoints Peggy Phillips to Board of Directors
PR Newswire - Mon Aug 22, 3:05PM CDT
PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA products to correct life-threatening inherited liver diseases in children, today announced the appointment of Peggy Phillips to the company's board of directors. Ms. Phillips will be replacing Richard Ulevitch, Ph.D., of 5AM Ventures, who is resigning from the board.
PZRX: 2.50 (-0.09)

PhaseRx Reports Second Quarter 2016 Financial Results and Provides Corporate Update
PR Newswire - Tue Aug 02, 3:05PM CDT
PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing treatments for life-threatening inherited liver diseases in children, today reported financial results for the quarter and six months ended June 30, 2016 and provided an update on its corporate activities.
PZRX: 2.50 (-0.09)

PhaseRx Advances Product Pipeline for Treatment of Rare Genetic Liver Diseases
PR Newswire - Tue Jun 21, 7:00AM CDT
PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing treatments for life-threatening inherited liver diseases in children, today announced product pipeline advancements including the selection of its lead product candidate, PRX-OTC, for treatment of Ornithine Transcarbamylase Deficiency (OTCD) and positive proof-of-concept data for a second product candidate, PRX-ASL, for treatment of Argininosuccinate Lyase Deficiency (ASLD).
PZRX: 2.50 (-0.09)

PhaseRx to Present at the 2016 JMP Securities Life Sciences Conference
PR Newswire - Wed Jun 15, 7:00AM CDT
PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing treatments for life-threatening inherited liver diseases in children, today announced that the company will be presenting at the 2016 JMP Securities Life Sciences Conference. Robert W. Overell, Ph.D., President and Chief Executive Officer, will provide an overview of the company and its development stage programs on Wednesday, June 22, 2016 at 9:30 a.m. EDT (6:30 a.m. PDT). The investor conference will be held from June 21-22, 2016 in New York.
PZRX: 2.50 (-0.09)

PhaseRx Announces Closing of Initial Public Offering
PR Newswire - Mon May 23, 3:00PM CDT
PhaseRx, Inc. (NASDAQZRX), a biotechnology company focused on developing mRNA therapeutics to treat orphan liver diseases, today announced the closing of its initial public offering of 3,700,000 shares of common stock at a public offering price of $5.00 per share, resulting in aggregate gross proceeds of $18.5 million, before underwriting discounts and commissions and offering related expenses. In addition, PhaseRx has granted the underwriters a 30-day option to purchase up to an additional 555,000 shares of common stock at the initial public offering price to cover over-allotments, if any. The company's common stock began trading on the NASDAQ Capital Market on May 18, 2016 under the symbol "PZRX."
PZRX: 2.50 (-0.09)

PhaseRx Announces Pricing of Initial Public Offering
PR Newswire - Tue May 17, 8:18PM CDT
PhaseRx, Inc. (NASDAQZRX), a biotechnology company focused on developing mRNA therapeutics to treat orphan liver diseases, today announced the pricing of its initial public offering of 3,700,000 shares of common stock at an initial public offering price of $5.00 per share for an aggregate offering of $18.5 million, before underwriting discounts and commissions. In addition, PhaseRx has granted the underwriters a 30-day option to purchase up to an additional 555,000 shares of common stock at the initial public offering price to cover over-allotments, if any.
PZRX: 2.50 (-0.09)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mango Board Honors Retailers Boosting Mango Sales

Updated Category News Views 97

The Unsung Heroes of the Mango Aisle You ever look around a grocery store and wonder who's behind those flashy displays that make a mango seem like the most appealing fruit in the aisle? Well, this year, four retailers got their pat on the back from the National Mango Board for doing just that—H-E-B, Rouses, Nugget Market, and Superior Grocers. Let me tell you, these...

Continue Reading
ePlus Schedules Q2 2027 Earnings Call Amid Corrections

Updated Category News Views 119

Earnings Date: Mark Your Calendar Well, folks, the date is set. ePlus Inc. is gearing up to drop some numbers that could stir the markets a bit. Come November 5th, those eagle-eyed investors better be on their toes because that’s when we’re getting the scoop on ePlus' second-quarter results for the fiscal year 2027. The bell rings after the market closes, so pour...

Continue Reading
Democracy's Living History at Long Island University

Updated Category News Views 76

America’s democracy is getting its moment in the spotlight over at Long Island University, and it's more than just statues and old papers. This exhibition, "The Presidency & Promise of America: A More Perfect Union," unpacked on October 28, throws open a window into the U.S.'s democratic journey from its scrappy beginnings to today’s hot zones of political debate. And...

Continue Reading
FOX News Sweeps 2026 Midterms Coverage Ratings

Updated Category News Views 11

FOX News Outshines Rivals in Midterm Coverage Diving into the chaos of the 2026 midterm elections, it’s clear FOX News Media’s strategic playbook outmaneuvered its cable competitors, chalking up a dominant ratings victory. Nielsen's final count places FOX News Channel (FNC) in the spotlight, their primetime broadcast drawing nearly 4.7 million viewers. And while some...

Continue Reading
Planet Fitness Flexes Financial Muscle in Q3 2026

Updated Category News Views 228

Financial Performance and Strategic Shifts Amidst a flurry of strategic maneuvers, Planet Fitness (NYSE: PLNT) cranked out a mixed but promising set of financial results for the third quarter of 2026. Revenue jumped 9.0% from last year to hit $360 million, a solid figure even if it came with a slight decrease in net income. It's a dance between growth and caution, folks....

Continue Reading
Gundry MD Unleashes MyoPeptide: A Powerhouse Supplement

Updated Category News Views 52

Creatine Gets a Makeover with MyoPeptide Well, here we have it! Gundry MD just rolled out their newest concoction, MyoPeptide Complex, and she's not your run-of-the-mill creatine shake. Blending creatine monohydrate with PeptiStrong®, a fava bean peptide, plus a couple of vitamins, this new supplement claims to turbocharge strength, recovery, and even your cognitive...

Continue Reading
MDA Space Q3 2026: Growth, Cash Flow Surge

Updated Category News Views 68

Revving Up in the Space Game Alright, let's talk MDA Space (TSX:MDA). Their third-quarter numbers for 2026 are in, and boy, they're not just floating aimlessly in space—this company is rocketing upward. Revenue hit $498 million, a solid 22% jump from last year. The kind of boost you'd expect when you've got a $40 billion opportunity pipeline and some new shiny tech...

Continue Reading
Qfin Faces Stock Lawsuit: Know Your Investor Rights

Updated Category News Views 100

Qfin in the Legal Hot Seat When you hear about a company's legal wranglings, especially one like Qfin Holdings, Inc., you've got to sit up and take notice. We're not talking about a quick scuffle here; this is a full-blown class action lawsuit with its talons sunk deep into allegations of securities law violations. They're squared off against DJS Law Group, an outfit that...

Continue Reading
Co-Diagnostics Moves Up Q3 Earnings Release to Nov. 10

Updated Category News Views 17

Co-Diagnostics Shifts Its Calendar Well, well, well, Co-Diagnostics decided to shake up its calendar. What are they looking to spill before the weekend? They’ve bumped up their third quarter 2026 earnings release by two days—an eyebrow-raiser for folks watching NASDAQ:CODX. Now they'll lay it all out on November 10, after we wrap up the trading day. I don’t want to...

Continue Reading
International Book Launch Celebrates Chinese Garden Art

Updated Category News Views 126

Book Celebrates the Harmony of Nature and Culture The dusty pages of history crack open yet again, but this time with an aromatic whiff of oriental garden artistry. Some might say books and gardens don't share much beyond paper, mulch, and soil. But hold tight. This isn't just any old launch—it's the Harmony Between the Universe: International Perspectives on the Lion...

Continue Reading

Top 5 Most Recently Viewed Articles

Youth Seek Security in Civil Service Amid Economic Challenges

Updated Category News Views 246

Chinese Youth Turn to Civil Service for Stability The demand for civil service jobs among the youth in China has surged remarkably, with a staggering 3.4 million candidates registering for the civil service exam this year. This trend can be largely attributed to the allure of job security in the face of a struggling economy and rising youth unemployment rates. With...

Continue Reading
Crawler Dozers Market Growth Soars to USD 13.2 Billion

Updated Category News Views 202

Expanding Crawler Dozers Market and Its Drivers The crawler dozers market is experiencing dynamic growth, with estimates suggesting an increase from approximately USD 8.5 billion in a couple of years to a substantial USD 13.2 billion by 2034. This remarkable growth, attributed to a compound annual growth rate (CAGR) of 4.6%, reflects the increasing need for advanced...

Continue Reading
New Floating-Rate Bonds Initiative Enhancing Funding Solutions

Updated Category News Views 167

New Floating-Rate Bonds Initiative Enhancing Funding Solutions Realkredit Danmark is set to launch new mortgage covered bonds (SDRO) aimed at financing the RD Nibor3® and RD Stibor3® initiatives. This step marks a significant move in the company's efforts to enhance its funding solutions and refine existing financial structures. In an ever-evolving financial landscape,...

Continue Reading
Earnings Preview: What Investors Should Know About Coursera

Updated Category News Views 74

Understanding Coursera's Upcoming Earnings Report Coursera (NYSE: COUR) is set to release its quarterly earnings soon, and there is much anticipation surrounding this event. For investors looking to make informed decisions, understanding the key details and insights surrounding this announcement is crucial. Analysts are projecting an earnings per share (EPS) of $0.02, and...

Continue Reading
Quantum BioPharma Offers $7 Million Reward for Insider Tips

Updated Category News Views 189

Quantum BioPharma Announces Whistleblower Cash Reward Quantum BioPharma Ltd. (NASDAQ: QNTM) is making significant waves in the biopharmaceutical industry with its innovative strategy designed to combat stock manipulation. The company has launched a whistleblower policy that offers a remarkable cash reward of up to USD $7 million to those who provide concrete evidence...

Continue Reading